Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

737 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The oncolytic virus, pelareorep, as a novel anticancer agent: a review.
Chakrabarty R, Tran H, Selvaggi G, Hagerman A, Thompson B, Coffey M. Chakrabarty R, et al. Among authors: coffey m. Invest New Drugs. 2015 Jun;33(3):761-74. doi: 10.1007/s10637-015-0216-8. Epub 2015 Feb 19. Invest New Drugs. 2015. PMID: 25693885 Review.
Evaluation of homogeneity and genetic stability of REOLYSIN (pelareorep) by complete genome sequencing of reovirus after large scale production.
Chakrabarty R, Tran H, Fortin Y, Yu Z, Shen SH, Kolman J, Onions D, Voyer R, Hagerman A, Serl S, Kamen A, Thompson B, Coffey M. Chakrabarty R, et al. Among authors: coffey m. Appl Microbiol Biotechnol. 2014 Feb;98(4):1763-70. doi: 10.1007/s00253-013-5499-0. Epub 2014 Jan 14. Appl Microbiol Biotechnol. 2014. PMID: 24419798
A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma.
Mahalingam D, Fountzilas C, Moseley J, Noronha N, Tran H, Chakrabarty R, Selvaggi G, Coffey M, Thompson B, Sarantopoulos J. Mahalingam D, et al. Among authors: coffey m. Cancer Chemother Pharmacol. 2017 Apr;79(4):697-703. doi: 10.1007/s00280-017-3260-6. Epub 2017 Mar 13. Cancer Chemother Pharmacol. 2017. PMID: 28289863 Clinical Trial.
Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors.
Gollamudi R, Ghalib MH, Desai KK, Chaudhary I, Wong B, Einstein M, Coffey M, Gill GM, Mettinger K, Mariadason JM, Mani S, Goel S. Gollamudi R, et al. Among authors: coffey m. Invest New Drugs. 2010 Oct;28(5):641-9. doi: 10.1007/s10637-009-9279-8. Epub 2009 Jul 2. Invest New Drugs. 2010. PMID: 19572105 Free PMC article. Clinical Trial.
A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.
Forsyth P, Roldán G, George D, Wallace C, Palmer CA, Morris D, Cairncross G, Matthews MV, Markert J, Gillespie Y, Coffey M, Thompson B, Hamilton M. Forsyth P, et al. Among authors: coffey m. Mol Ther. 2008 Mar;16(3):627-32. doi: 10.1038/sj.mt.6300403. Epub 2008 Feb 5. Mol Ther. 2008. PMID: 18253152 Free article. Clinical Trial.
Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.
Twigger K, Roulstone V, Kyula J, Karapanagiotou EM, Syrigos KN, Morgan R, White C, Bhide S, Nuovo G, Coffey M, Thompson B, Jebar A, Errington F, Melcher AA, Vile RG, Pandha HS, Harrington KJ. Twigger K, et al. Among authors: coffey m. BMC Cancer. 2012 Aug 24;12:368. doi: 10.1186/1471-2407-12-368. BMC Cancer. 2012. PMID: 22920673 Free PMC article.
737 results